Literature DB >> 14716072

Cystic fibrosis in adults: current and future management strategies.

Brian M Morrissey1, Bettina C Schock, Gregory P Marelich, Carroll E Cross.   

Abstract

Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.

Entities:  

Mesh:

Year:  2003        PMID: 14716072     DOI: 10.1385/CRIAI:25:3:275

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  68 in total

Review 1.  Nuclear transplantation, embryonic stem cells, and the potential for cell therapy.

Authors:  Konrad Hochedlinger; Rudolf Jaenisch
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

Review 2.  Mechanisms of antibiotic resistance in Pseudomonas aeruginosa.

Authors:  P A Lambert
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

3.  Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease.

Authors:  K J Friedman; R A Heim; M R Knowles; L M Silverman
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

4.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.

Authors:  J P Clancy; Z Bebök; F Ruiz; C King; J Jones; L Walker; H Greer; J Hong; L Wing; M Macaluso; R Lyrene; E J Sorscher; D M Bedwell
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

5.  Abnormal glutathione transport in cystic fibrosis airway epithelia.

Authors:  L Gao; K J Kim; J R Yankaskas; H J Forman
Journal:  Am J Physiol       Date:  1999-07

6.  Outcomes of intensive care unit care in adults with cystic fibrosis.

Authors:  N Sood; L J Paradowski; J R Yankaskas
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

Review 7.  Effects of drugs on mucus clearance.

Authors:  E Houtmeyers; R Gosselink; G Gayan-Ramirez; M Decramer
Journal:  Eur Respir J       Date:  1999-08       Impact factor: 16.671

8.  Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3.

Authors:  Bifeng Gao; Sonia C Flores; Jonathan A Leff; Swapan K Bose; Joe M McCord
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-01-10       Impact factor: 5.464

Review 9.  Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies.

Authors:  P Birrer
Journal:  Respiration       Date:  1995       Impact factor: 3.580

Review 10.  Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?

Authors:  V Witko-Sarsat; I Sermet-Gaudelus; G Lenoir; B Descamps-Latscha
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.